摘要
目的观察补益强心片治疗慢性心力衰竭的疗效及安全性。方法将60例慢性心力衰竭患者随机分为对照组和治疗组各30例。对照组给予常规西药纠正慢性心力衰竭治疗,治疗组在常规西药治疗的基础上联合应用补益强心片口服,疗程为4周。观察治疗前后两组患者的临床疗效、心功能指标改变(LVEDD、LVEF)、血浆BNP水平改变及明尼苏达心衰生活质量评分改变,并观察两组患者治疗过程中出现的不良反应情况。结果与治疗前相比,治疗组患者心功能改善的总有效率高于对照组(P<0.05);两组心彩超中心功能指标(LVEDD、LVEF)较治疗前均有改善,但治疗组改善更为明显,与对照组比较差异有统计学意义(P<0.05);治疗后,治疗组与对照组比较,血浆BNP水平下降更为明显(P<0.01),明尼苏达心衰生活质量评分升高更为明显(P<0.01)。结论在常规西医治疗基础上联合应用补益强心片可以进一步改善慢性心力衰竭患者的临床症状、心功能和生活质量。
Objective To observe the clinical effects and safety of chronic heart failure with Buyiqiangxinpian. Methods 60 patients with CHF from the inpatient department were randomly divided into two groups each 30. The control group was treated with base heart failure therapy, while the treatment group was treated with Buyiqiangxinpian as well as the base heart failure therapy, treatment for 4 weeks. Observation before and after the treatment of clinical efficacy, heart function index of doppler examination （LVEDD, LVEF）, the level of BNP in plasma, the Minnesota heart failure score of life quality, and the adverse reaction of all patients during the treatment. Results After the treatment, the total efficiency of heart function improved in the treatment group is higher than that in the control group （P〈0.05）. After the treatment, heart function index of doppler examination （LVEDD, LVEF） have improved both in two groups, but the treatment group improved more significantly, and there were statiscaily significant differences between two groups（P〈0.05）. The plasma BNP level decreased more obviously in the treatment group compared with the control group（P〈0.01）. The Minnesota heart failure score of life quality increased more significantly （P〈0.01）. Conclusion Treatment of base heart failure therapy combined with Buyiqiangxinpian can improve clinical symptoms, heart function and life quality of patients with chronic heart failure more effectively.
出处
《中国医药指南》
2013年第23期24-26,共3页
Guide of China Medicine
关键词
补益强心片
慢性心力衰竭
临床观察
Buyiqiangxinpian
Chronic heart failure
Clinical observation
